Skip to main content

Search

Reset all filters
729 Result(s)
Sort by

Candice is moving to Germany

Candice is moving to Germany

Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.
Work life wellness

Work life wellness

We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
New initiative elevates the importance of CKD testing

New initiative elevates the importance of CKD testing

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com
Something learnt

Something learnt

We know that to really thrive as a company, we have to help our teams to continue to grow in their careers. Here are some of things they have learnt at work.
Emmanuelle leads a team of scientists

Emmanuelle leads a team of scientists

Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.
More Health Overview

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
R&D - Transforming tomorrow

R&D - Transforming tomorrow

Manami Tsutsumi, Senior Associate Director in Research & Development describes what it is like working on the cutting edge of pharmaceutical development.
Partnering Culture

Partnering Culture

BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.
Clinical Trials

Clinical Trials

Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.
FDA approved treatment option for adults with CKD

FDA approved treatment option for adults with CKD

The FDA has approved Jardiance® (empagliflozin) tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with CKD at risk of progression.